transparency

A new regulation and registry covering investigational medicinal products mandates reporting and supports multinational trials.

The sponsors of upwards of 1,000 clinical trials may be forced to publish data that have gone unpublished over a 10-year period.

The nonprofit newsroom has collected more than 29,000 disclosures of faculty members’ outside income, but they represent just the tip of the iceberg.

The changes would further restrict which scientific findings can be used in drafting regulations.

Many preclinical studies carried out in vivo are poorly designed and generate irreproducible data, but efforts to address the problem are on the rise.

Research organizations should start sharing with the public information, stories, photos, and videos on how animals are cared for and used in science.

In service of an arbitrary threshold, p-values often lead researchers to make poorly supported claims and ignore interesting but insignificant results, scientists argue.

The Stanford University researcher discusses a new study on measures such as data sharing and funding disclosures.

It will be more than a year before the agency institutes or rejects the controversial changes proposed by former EPA head Scott Pruitt.

The original work found that an anti-malaria drug or the neurotransmitter GABA could increase the number of insulin-producing pancreatic cells in mice.

The Reproducibility Project: Cancer Biology initially aimed to replicate the results of 50 high-impact research articles.

Nearly 600 signatories, including four Nobel Prize winners, urge openness about animal experiments.

The cofounder of the EQUATOR Network devoted his career to boosting transparency and improving the quality of clinical research.

Republican politicians have been trying to limit data to only those publicly available, but opponents say that would neglect private, yet important, information.

The BMJ inquiry finds that researchers presented only select results from animal experiments when applying for funding and approval for human trials.

The use of underperforming computational tools is a major offender in science’s reproducibility crisis—and there’s growing momentum to avoid it.

The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.

The authors of two new studies on the payments suggest stricter guidelines are needed.

The publisher will ask its journal editors to adopt widely accepted standards on transparency and openness in scientific communication.